{
    "xml": "<topic id=\"PHP81533\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/hbvaxpro\" basename=\"hbvaxpro\" title=\"HBvaxPRO\">\n<title>HBvaxPRO<tm tmtype=\"reg\"/>\n</title>\n<topic id=\"PHP81824\" outputclass=\"indicationsAndDose\" rev=\"1.50\" parent=\"/clinical-medicinal-product-information/hbvaxpro\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Immunisation against hepatitis B infection</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup neonate\">\n<p>Neonate</p>\n<p>5&#8239;micrograms for 1 dose, followed by 5&#8239;micrograms after 1&#8239;month for 1 dose, then 5&#8239;micrograms after 5&#8239;months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), dose not to be used for neonate born to hepatitis B surface antigen positive mother.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 1 month&#8211;15 years</p>\n<p>5&#8239;micrograms for 1 dose, followed by 5&#8239;micrograms after 1&#8239;month for 1 dose, then 5&#8239;micrograms after 5&#8239;months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 16&#8211;17 years</p>\n<p>10&#8239;micrograms for 1 dose, followed by 10&#8239;micrograms after 1&#8239;month for 1 dose, followed by 10&#8239;micrograms after 5&#8239;months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>10&#8239;micrograms for 1 dose, followed by 10&#8239;micrograms after 1&#8239;month for 1 dose, followed by 10&#8239;micrograms after 5&#8239;months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Immunisation against hepatitis B infection (accelerated schedule)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup neonate\">\n<p>Neonate</p>\n<p>5&#8239;micrograms every 1&#8239;month for 3 months, followed by 5&#8239;micrograms after 9&#8239;months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), dose not to be used for neonate born to hepatitis B surface antigen positive mother.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 1 month&#8211;15 years</p>\n<p>5&#8239;micrograms every 1&#8239;month for 3 months, followed by 5&#8239;micrograms after 9&#8239;months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 16&#8211;17 years</p>\n<p>10&#8239;micrograms every 1&#8239;month for 3 months, followed by 10&#8239;micrograms after 9&#8239;months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>10&#8239;micrograms every 1&#8239;month for 3 months, followed by 10&#8239;micrograms after 9&#8239;months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Neonate born to hepatitis B surface antigen-positive mother</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup neonate\">\n<p>Neonate</p>\n<p>5&#8239;micrograms every 1&#8239;month for 3 months, first dose given at birth with hepatitis B immunoglobulin injection (separate site), followed by 5&#8239;micrograms after 9&#8239;months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Chronic haemodialysis patients</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 16&#8211;17 years</p>\n<p>40&#8239;micrograms every 1&#8239;month for 2 months, followed by 40&#8239;micrograms after 5&#8239;months for 1 dose, booster doses may be required in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>40&#8239;micrograms every 1&#8239;month for 2 months, followed by 40&#8239;micrograms after 5&#8239;months for 1 dose, booster doses may be required in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP81533",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/hbvaxpro",
    "basename": "hbvaxpro",
    "title": "HBvaxPRO",
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Immunisation against hepatitis B infection",
                        "html": "Immunisation against hepatitis B infection"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "neonate": [
                    {
                        "textContent": "5 micrograms for 1 dose, followed by 5 micrograms after 1 month for 1 dose, then 5 micrograms after 5 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), dose not to be used for neonate born to hepatitis B surface antigen positive mother.",
                        "html": "<p>5&#8239;micrograms for 1 dose, followed by 5&#8239;micrograms after 1&#8239;month for 1 dose, then 5&#8239;micrograms after 5&#8239;months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), dose not to be used for neonate born to hepatitis B surface antigen positive mother.</p>"
                    }
                ],
                "child": [
                    {
                        "textContent": "5 micrograms for 1 dose, followed by 5 micrograms after 1 month for 1 dose, then 5 micrograms after 5 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>5&#8239;micrograms for 1 dose, followed by 5&#8239;micrograms after 1&#8239;month for 1 dose, then 5&#8239;micrograms after 5&#8239;months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants; not to be injected into the buttock (vaccine efficacy reduced).</p>",
                        "ageGroup": "1 month&#8211;15 years"
                    },
                    {
                        "textContent": "10 micrograms for 1 dose, followed by 10 micrograms after 1 month for 1 dose, followed by 10 micrograms after 5 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>10&#8239;micrograms for 1 dose, followed by 10&#8239;micrograms after 1&#8239;month for 1 dose, followed by 10&#8239;micrograms after 5&#8239;months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>",
                        "ageGroup": "16&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "10 micrograms for 1 dose, followed by 10 micrograms after 1 month for 1 dose, followed by 10 micrograms after 5 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>10&#8239;micrograms for 1 dose, followed by 10&#8239;micrograms after 1&#8239;month for 1 dose, followed by 10&#8239;micrograms after 5&#8239;months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Immunisation against hepatitis B infection (accelerated schedule)",
                        "html": "Immunisation against hepatitis B infection (accelerated schedule)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "neonate": [
                    {
                        "textContent": "5 micrograms every 1 month for 3 months, followed by 5 micrograms after 9 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), dose not to be used for neonate born to hepatitis B surface antigen positive mother.",
                        "html": "<p>5&#8239;micrograms every 1&#8239;month for 3 months, followed by 5&#8239;micrograms after 9&#8239;months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), dose not to be used for neonate born to hepatitis B surface antigen positive mother.</p>"
                    }
                ],
                "child": [
                    {
                        "textContent": "5 micrograms every 1 month for 3 months, followed by 5 micrograms after 9 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>5&#8239;micrograms every 1&#8239;month for 3 months, followed by 5&#8239;micrograms after 9&#8239;months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants; not to be injected into the buttock (vaccine efficacy reduced).</p>",
                        "ageGroup": "1 month&#8211;15 years"
                    },
                    {
                        "textContent": "10 micrograms every 1 month for 3 months, followed by 10 micrograms after 9 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>10&#8239;micrograms every 1&#8239;month for 3 months, followed by 10&#8239;micrograms after 9&#8239;months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>",
                        "ageGroup": "16&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "10 micrograms every 1 month for 3 months, followed by 10 micrograms after 9 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>10&#8239;micrograms every 1&#8239;month for 3 months, followed by 10&#8239;micrograms after 9&#8239;months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Neonate born to hepatitis B surface antigen-positive mother",
                        "html": "Neonate born to hepatitis B surface antigen-positive mother"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "neonate": [
                    {
                        "textContent": "5 micrograms every 1 month for 3 months, first dose given at birth with hepatitis B immunoglobulin injection (separate site), followed by 5 micrograms after 9 months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>5&#8239;micrograms every 1&#8239;month for 3 months, first dose given at birth with hepatitis B immunoglobulin injection (separate site), followed by 5&#8239;micrograms after 9&#8239;months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Chronic haemodialysis patients",
                        "html": "Chronic haemodialysis patients"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "child": [
                    {
                        "textContent": "40 micrograms every 1 month for 2 months, followed by 40 micrograms after 5 months for 1 dose, booster doses may be required in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>40&#8239;micrograms every 1&#8239;month for 2 months, followed by 40&#8239;micrograms after 5&#8239;months for 1 dose, booster doses may be required in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>",
                        "ageGroup": "16&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "40 micrograms every 1 month for 2 months, followed by 40 micrograms after 5 months for 1 dose, booster doses may be required in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>40&#8239;micrograms every 1&#8239;month for 2 months, followed by 40&#8239;micrograms after 5&#8239;months for 1 dose, booster doses may be required in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>"
                    }
                ]
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}